Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1984 2
1992 1
1995 1
1998 1
2001 1
2003 1
2005 2
2006 1
2008 1
2009 3
2010 2
2011 1
2012 4
2013 2
2014 2
2015 4
2016 3
2017 2
2018 3
2019 5
2020 1
2021 3
2022 3
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Results by year

Filters applied: . Clear all
Page 1
The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group.
Siris ES, Adler R, Bilezikian J, Bolognese M, Dawson-Hughes B, Favus MJ, Harris ST, Jan de Beur SM, Khosla S, Lane NE, Lindsay R, Nana AD, Orwoll ES, Saag K, Silverman S, Watts NB. Siris ES, et al. Osteoporos Int. 2014 May;25(5):1439-43. doi: 10.1007/s00198-014-2655-z. Epub 2014 Feb 28. Osteoporos Int. 2014. PMID: 24577348 Free PMC article.
In the USA, the standard criterion for the diagnosis of osteoporosis in postmenopausal women and older men is a T-score of -2.5 at the lumbar spine, femur neck, or total hip by bone mineral density testing. METHODS: Under the direction of the National Bone Health Al …
In the USA, the standard criterion for the diagnosis of osteoporosis in postmenopausal women and older men is a T-score of -2.5 at the lumba …
Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review.
Fink HA, MacDonald R, Forte ML, Rosebush CE, Ensrud KE, Schousboe JT, Nelson VA, Ullman K, Butler M, Olson CM, Taylor BC, Brasure M, Wilt TJ. Fink HA, et al. Ann Intern Med. 2019 Jul 2;171(1):37-50. doi: 10.7326/M19-0533. Epub 2019 Apr 23. Ann Intern Med. 2019. PMID: 31009947 Free article.
BACKGROUND: Optimal long-term osteoporosis drug treatment (ODT) is uncertain. PURPOSE: To summarize the effects of long-term ODT and ODT discontinuation and holidays. ...
BACKGROUND: Optimal long-term osteoporosis drug treatment (ODT) is uncertain. PURPOSE: To summarize the effects of long-term O …
Definition and Evolution of the Term Osteoporosis.
Poduval M, Vishwanathan K. Poduval M, et al. Indian J Orthop. 2023 Oct 31;57(Suppl 1):42-44. doi: 10.1007/s43465-023-01013-2. eCollection 2023 Dec. Indian J Orthop. 2023. PMID: 38107798 Review.
Osteoporosis is a metabolic bone disease in which the loss of bone mineral density causes the bone to become weaker and more susceptible to fracture. In the vulnerable individual, osteoporosis develops as a result of a combination of hereditary and environmen …
Osteoporosis is a metabolic bone disease in which the loss of bone mineral density causes the bone to become weaker and …
Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk--a perspective.
Boonen S, Ferrari S, Miller PD, Eriksen EF, Sambrook PN, Compston J, Reid IR, Vanderschueren D, Cosman F. Boonen S, et al. J Bone Miner Res. 2012 May;27(5):963-74. doi: 10.1002/jbmr.1570. Epub 2012 Mar 29. J Bone Miner Res. 2012. PMID: 22467094 Free article. Review.
Osteoporosis may be a lifelong condition. Robust data regarding the efficacy and safety of both long-term osteoporosis therapy and therapy discontinuation are therefore important. ...Similarly, the effects of rapid reversal of bone turnover upon discontinuati …
Osteoporosis may be a lifelong condition. Robust data regarding the efficacy and safety of both long-term osteoporosis therapy …
Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab.
Kendler DL, Bone HG, Massari F, Gielen E, Palacios S, Maddox J, Yan C, Yue S, Dinavahi RV, Libanati C, Grauer A. Kendler DL, et al. Osteoporos Int. 2019 Dec;30(12):2437-2448. doi: 10.1007/s00198-019-05146-9. Epub 2019 Oct 18. Osteoporos Int. 2019. PMID: 31628490 Free PMC article. Clinical Trial.
However, for long-term osteoporosis management, a second treatment course may be appropriate. Romosozumab, a therapy with the dual effect of increasing bone formation and decreasing bone resorption, reduces fracture risk within 12 months. ...
However, for long-term osteoporosis management, a second treatment course may be appropriate. Romosozumab, a therapy with the …
Emerging concepts in osteoporosis and bone strength.
Rubin CD. Rubin CD. Curr Med Res Opin. 2005 Jul;21(7):1049-56. doi: 10.1185/030079905X50525. Curr Med Res Opin. 2005. PMID: 16004672 Review.
OBJECTIVE: Osteoporosis is a systemic skeletal disorder characterized by compromised bone strength and increased fracture risk. The factors that contribute to bone strength include bone mineral density (BMD) and bone quality, which encompasses factors …
OBJECTIVE: Osteoporosis is a systemic skeletal disorder characterized by compromised bone strength and increased fracture risk. The f …
Osteoporosis: the evolution of a scientific term.
Schapira D, Schapira C. Schapira D, et al. Osteoporos Int. 1992 Jul;2(4):164-7. doi: 10.1007/BF01623921. Osteoporos Int. 1992. PMID: 1611220 Review.
Coined in French in the early 1820s as a mere description of a pathological state of the bone, the term 'osteoporosis' made its way into the English medical vocabulary only in the twentieth century. ...
Coined in French in the early 1820s as a mere description of a pathological state of the bone, the term 'osteoporosis' …
Cognitive impairment and risks of osteoporosis: A systematic review and meta-analysis.
Zhao Y, Chen H, Qiu F, He J, Chen J. Zhao Y, et al. Arch Gerontol Geriatr. 2023 Mar;106:104879. doi: 10.1016/j.archger.2022.104879. Epub 2022 Nov 25. Arch Gerontol Geriatr. 2023. PMID: 36462246 Free article. Review.
METHOD: A comprehensive research of Embase, Cochrane Library, PubMed, Web of Science, CNKI, Wangfang Data and VIP was performed from inception to January 2022, using the search term 'osteoporosis' and 'cognitive impairment'. Literature screening, data extraction and …
METHOD: A comprehensive research of Embase, Cochrane Library, PubMed, Web of Science, CNKI, Wangfang Data and VIP was performed from incepti …
Efficacy and safety of odanacatib for osteoporosis treatment: a systematic review and meta-analysis.
Chen R, Chen C, Geng B, Yang C, Xiao H, Yang F, Wang H, Xia Y. Chen R, et al. Arch Osteoporos. 2023 May 11;18(1):67. doi: 10.1007/s11657-023-01261-7. Arch Osteoporos. 2023. PMID: 37169994 Review.
The primary outcomes were the percentage change in markers of bone turnover and bone formation as well as that in the bone mineral density (BMD) of the lumbar spine, hip, femoral neck, and greater trochanter. ...However, significant differences in fracture an …
The primary outcomes were the percentage change in markers of bone turnover and bone formation as well as that in the bone …
50 results